Dechra Pharmaceuticals PLCDPH:LSE

657.00
10.50 / 1.57%
128.02k
11.87%
0.2082
Close in GBXToday's changeShares traded1 year changeBeta
As of Apr 17 2014 17:37 BST.Data delayed by at least 15 minutes.

Summary

On Thursday, Dechra Pharmaceuticals PLC (DPH:LSE) closed at 657.00, 0.25% above its 52-week low of 655.38, set on Jul 10, 2013.

52-week range
Today
655.38
Jul 10 2013
765.00
Apr 19 2013
Open659.50
Day high668.00
Day low657.00
Bid--
Offer--
Previous close667.50
Average volume92.36k
Shares outstanding87.66m
Free float84.70m
P/E (TTM)41.40
Market cap585.13m GBP
EPS (TTM)0.1612 GBP
Annual div (TTM)14.41 GBX
Annual div yield (TTM)2.16%
Div ex-dateMar 12 2014
Div pay-dateApr 08 2014
Last IC View
The last IC recommendation on Dechra Pharmaceuticals PLC shares was Hold at 685.00 on 25 Feb 2014
Read the full article

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Dechra Pharmaceuticals PLC-3.31%-5.60%-3.52%-11.87%+82.23%
FTSE 100 Index-0.25%+0.87%+0.75%+6.10%+61.88%
As of Apr 17 2014 17:37 BST.Data delayed by at least 15 minutes.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.